HC Wainwright Analysts Give Veru (VERU) a $5.00 Price Target

Share on StockTwits

HC Wainwright set a $5.00 target price on Veru (NASDAQ:VERU) in a research report released on Thursday morning. The brokerage currently has a buy rating on the stock.

Several other brokerages have also recently weighed in on VERU. Maxim Group initiated coverage on Veru in a report on Tuesday, July 3rd. They set a buy rating for the company. Zacks Investment Research cut Veru from a hold rating to a sell rating in a report on Tuesday, August 21st. Dawson James reissued a buy rating on shares of Veru in a report on Monday, June 25th. Finally, ValuEngine raised Veru from a hold rating to a buy rating in a report on Wednesday, August 15th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of $5.83.

Shares of NASDAQ:VERU opened at $1.78 on Thursday. Veru has a 1-year low of $0.90 and a 1-year high of $3.00. The company has a current ratio of 1.01, a quick ratio of 0.80 and a debt-to-equity ratio of 0.12.

Veru (NASDAQ:VERU) last announced its quarterly earnings data on Tuesday, August 14th. The company reported ($0.15) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.07). The firm had revenue of $5.50 million for the quarter, compared to the consensus estimate of $5.20 million. Veru had a negative return on equity of 38.09% and a negative net margin of 130.26%. equities analysts expect that Veru will post -0.33 EPS for the current fiscal year.

An institutional investor recently bought a new position in Veru stock. ACG Wealth purchased a new stake in Veru Inc (NASDAQ:VERU) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 77,000 shares of the company’s stock, valued at approximately $156,000. ACG Wealth owned about 0.14% of Veru at the end of the most recent reporting period. Hedge funds and other institutional investors own 5.20% of the company’s stock.

Veru Company Profile

Veru Inc operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.

Featured Article: How Do You Make Money With Penny Stocks?

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Cubist Systematic Strategies LLC Has $997,000 Position in ServiceNow Inc
Cubist Systematic Strategies LLC Has $997,000 Position in ServiceNow Inc
Royal Gold  Lowered to Sell at Zacks Investment Research
Royal Gold Lowered to Sell at Zacks Investment Research
Rollins  Now Covered by Analysts at Gabelli
Rollins Now Covered by Analysts at Gabelli
Kepler Capital Markets Reiterates €35.00 Price Target for Innogy
Kepler Capital Markets Reiterates €35.00 Price Target for Innogy
Delivery Hero  PT Set at €57.00 by Morgan Stanley
Delivery Hero PT Set at €57.00 by Morgan Stanley
Dynamic Technology Lab Private Ltd Takes Position in Enel Americas SA
Dynamic Technology Lab Private Ltd Takes Position in Enel Americas SA


Leave a Reply

© 2006-2018 Ticker Report. Google+.